1 / 7

Health Technology Assessment

Health Technology Assessment. Presenter: Chrissie Fletcher Facilitator: Christoph Gerlinger. The Fourth Hurdle. What the Regulatory/HTA Interface might look like in the future – EMA Perspective*. * How Regulatory Agencies could interact with Health Technology Bodies, Presentation at

makani
Download Presentation

Health Technology Assessment

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Health Technology Assessment Presenter: Chrissie Fletcher Facilitator: Christoph Gerlinger

  2. The Fourth Hurdle

  3. What the Regulatory/HTA Interface might look like in the future – EMA Perspective* * How Regulatory Agencies could interact with Health Technology Bodies, Presentation at DIA, Berlin, March 2009, by Thomas Lonngren, EMA

  4. Target/Candidate Selection Reimbursement: desk research, external advice* Develop/test value hypotheses Hypothesize Burden of Illness, unmet need Target endpoints and claims , ?PRO development Assess reimbursement and access needs VALUE PROPOSITION Phase I Early economic modelling, pricing research PhIIb: Ensure clinical devt plans address payer needs Identify possible sub-populations Phase II/POC Substantiate PRO validation (if required) PhIII: Meaningful endpoints, comparators Burden of Illness Studies Phase IIb Integrate ‘Value Dossier’ and local submissions Economic model, budget impact model(s) PRO analyses Phase III Communicate ‘Real World ‘ effectiveness, cost-effectiveness ‘Managed Access’: further study commitments Adapt models, disease management tools Phase IV/Post Marketing Health Outcomes in Product Development *External advisors/payer input obtained iteratively throughout product development Based on: Sollano JA, Kirsch J, Bala MV, Chambers MG et. al. Clinical Pharmacology & Therapeutics (2008); 84, 2, 263–26

  5. Relationship clinical development – HEOR/HTA • In the past: work in parallel w/o much interaction • HEOR/HTA „recycled“ the clinical study data • Today & future: • Incorporation of HTA data needs into planning of clincial development programme • Joint PRO validation activities • Partnership between statisticians and 4th hurdle collagues, e.g. Health Economics, HTA Policy/Corporate Affairs, Pricing

  6. Skills sets in HTA • Observational research versus interventional research • Linking “efficacy” with “effectiveness” • Economic related outcomes • Health resource utilisation measures • Evidence synthesis • indirect/mixed treatment comparisons • Subgroups/subpopulations of interest • Modelling life-time clinical and cost outcomes • use of surrogate endpoints

  7. Suggested points for discussion • Is the HTA area seen as an area where statisticians should be involved? • If yes, • Are statisticians in the industry sufficiently equipped to deal with the statistical challenges faced in HTA research? • How can EFPSI promote the statistical profession in the HTA area?

More Related